Access peer-reviewed journal articles sponsored by Dyne Therapeutics offering insights into the FORCE™ platform.
The FORCE™ platform, zeleciment-basivarsen (z-basivarsen, also known as DYNE-101), zeleciment-rostudirsen (z-rostudirsen, also known as DYNE-251), DYNE-302, and DYNE-401 are investigational or otherwise in development and have not been approved as safe or effective by the US FDA, EMA or any other regulatory authority.
Dyne Therapeutics, Inc. supports accredited continuing education (CE) for healthcare professionals across therapeutic areas of interest. These CE activities are planned, developed and delivered by independent accredited providers in accordance with the standards set forth in the ACCME Standards for Integrity and Independence in Accredited Continuing Education, or the standards of other similar accrediting organizations. Dyne Therapeutics, Inc. does not exercise control over, or provide guidance to, any accredited provider. Dyne Therapeutics, Inc. is sharing CE information on this page as a service to the medical community and with permission from the accredited providers. The information on this page is intended to provide self-service to educational topics of interest, and most activities are free to the learner (some may require a nominal registration fee per the accredited provider's requirements).